Joanne Quan Sells 6,969 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,969 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $45.86, for a total value of $319,598.34. Following the sale, the insider now directly owns 5,649 shares in the company, valued at $259,063.14. This represents a 55.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $46.72 on Thursday. The firm’s fifty day moving average price is $43.59 and its two-hundred day moving average price is $41.36. The stock has a market cap of $2.24 billion, a PE ratio of -23.13 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Mirum Pharmaceuticals’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.57) EPS. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MIRM. Amalgamated Bank increased its position in Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the last quarter. Avanza Fonder AB acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $189,000. ProShare Advisors LLC bought a new position in Mirum Pharmaceuticals during the 2nd quarter worth $213,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Mirum Pharmaceuticals during the 3rd quarter worth about $215,000.

Wall Street Analysts Forecast Growth

MIRM has been the topic of several analyst reports. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Citigroup increased their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners lifted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.